Phase 2RecruitingPriority 3 · Moderate priorityNCT05833893
Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Plain-language summary
This trial is testing XPO1 inhibitor for patients with extranodal NK/T-cell lymphoma (ENKTL) who have been newly diagnosed and have not yet received treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial does not currently have sites in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 14 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
XPO1 inhibitor (DRUG): COPL + XPO1 inhibitor (Selinexor, 60 mg, po., d1,8,15)
XPO1 inhibitor
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details